We sell integrated systems of instruments and equipment, software and reagents to biomedical and biopharmaceutical researchers that we believe improve the productivity and efficiency of the drug discovery and development process. Using the detection and measurement of photons emitted from cells and animals that we genetically engineer to emit light, which we term “biophotonic imaging,” our patented and proprietary biophotonic IVIS Imaging Systems, living animal models and research services collectively expeditein vivo data collection and analysis, a critical bottleneck in drug discovery and development. Our customers usein vivo biophotonic imaging to visually display and quantify a chosen tumor, disease, pathogen, organ or biochemical reaction. Our products are also used to generate predictive animal models, primarily rats and mice, for preclinical drug discovery and development. We believe our products enable our pharmaceutical and biotechnology customers to generate higher-quality safety and efficacy data for drug candidates, to
Company profile
Ticker
XGEN
Exchange
CEO
John E. Myers
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
770412269
Latest filings (excl ownership)
15-12G
Securities registration termination
9 Aug 06
25-NSE
Exchange delisting
9 Aug 06
DEFA14A
Additional proxy soliciting materials
4 Aug 06
425
Business combination disclosure
14 Jul 06
8-K
Caliper Life Sciences and Xenogen Announce
14 Jul 06
DEFA14A
Additional proxy soliciting materials
14 Jul 06
425
Business combination disclosure
13 Jul 06
DEFM14A
Proxy related to merger
12 Jul 06
8-K
Entry into a Material Definitive Agreement
6 Jul 06
425
Business combination disclosure
15 Jun 06
Latest ownership filings
No filings